Skip to main content
main-content

18-07-2017 | Colorectal cancer | Article

Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?

Journal:
Cancer Chemotherapy and Pharmacology

Authors: Thomas B. Karasic, Mark A. Rosen, Peter J. O’Dwyer

Publisher: Springer Berlin Heidelberg

Abstract

Antiangiogenic therapy has a proven survival benefit in metastatic colorectal cancer. Inhibition of the VEGF pathway using a variety of extracellular antibody approaches has clear benefit in combination with chemotherapy, while intracellular blockade using tyrosine kinase inhibitors (TKIs) such as sorafenib and regorafenib has had more limited success. Pharmacodynamic modeling using modalities such as DCE-MRI indicates potent antiangiogenic effects of these TKIs, yet numerous combination therapies, primarily with chemotherapy, have failed to demonstrate an additive benefit. The sole comparative study of a single agent TKI against placebo showed a survival benefit of regorafenib in patients with advanced, refractory disease. Preclinical data demonstrate synergy between antiantiogenic TKIs and targeted interventions including autophagy inhibition, and together with a renewed effort to define markers of susceptibility, such combinations may be a way to improve the limited efficacy of this once-promising drug class.

Please log in to get access to this content

Related topics